WASHINGTON — The Biden administration’s proposal to loosen federal restrictions on marijuana is dividing some of the nation’s top medical professionals.
The nation’s largest and most powerful doctors group, the American Medical Association, has raised multiple concerns with the move, which is known as rescheduling. The American Psychiatric Association has said the drug should remain a Schedule I substance, like heroin, one deemed to have no proven medical value and a high risk of abuse. The American Academy of Neurology has said that restrictions should only be loosened slightly, and that the drug should be regulated like fentanyl and oxycodone.
The move is supported, however, by the American Nurses Association and the American Academy of Hospice and Palliative Medicine, as well as the American Association of Medical Colleges.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
